(Q34353067)

1 August 2017

1 reference

title

Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram (English)

1 reference

1 August 2017

1 reference

1 reference

Brøsen K

1 reference

1 August 2017

Naranjo CA

series ordinal

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

European Neuropsychopharmacology

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

275-283

1 reference

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

A "therapeutic window" with citalopram in a case of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Citalopram and clozapine: potential drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The pharmacogenetics of the selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Differences in interactions of SSRIs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The kinetics of citalopram: single and multiple dose studies in man

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Lack of Adverse Interactions Between Concomitantly Administered Selegiline and Citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Lack of citalopram effect on oral digoxin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Fatality caused by a combined trimipramine-citalopram intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Effect of citalopram on plasma levels of oral theophylline

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Lack of interaction between citalopram and the CYP3A4 substrate triazolam

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Studies on the Stereoselective Metabolism of Citalopram by Human Liver Microsomes and cDNA-Expressed Cytochrome P450 Enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Pharmacokinetic interaction study of citalopram and cimetidine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Multidrug-resistance transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Inhibitors of imipramine metabolism by human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Co-administration of citalopram and clozapine: effect on plasma clozapine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

Interaction of fluoxetine with tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900101-8

7 January 2021

10.1016/S0924-977X(01)00101-8

Identifiers

DOI

1 reference

1 August 2017

1 reference